Loading...
•
Sep 30, 2021
Progyny Q3 2021 Earnings Report
Progyny's Q3 2021 results were announced, demonstrating strong revenue growth and margin expansion.
Key Takeaways
Progyny reported a 24% increase in revenue, reaching $122.3 million for the third quarter of 2021. The company added more than 85 new clients, representing approximately 1.2 million new covered lives for 2022. Margins expanded significantly, and the company generated substantial operating cash flow.
Revenue grew by 24% compared to the prior year period.
Margins expanded significantly year-over-year.
The company generated a substantial amount of operating cash flow.
More than 85 new clients were added, representing an estimated 1.2 million new covered lives for 2022.
Revenue by Segment
Forward Guidance
Progyny anticipates revenue growth of approximately 50% in 2022. For the fourth quarter of 2021, revenue is projected to be $133.9 million to $140.9 million, reflecting growth of 34% to 41%. Net income is projected to be $0.8 million to $3.4 million, or $0.01 to $0.03 per diluted share. Adjusted EBITDA is projected to be $16.8 million to $18.3 million.
Positive Outlook
- Revenue is projected to be $133.9 million to $140.9 million, reflecting growth of 34% to 41%
- Net income is projected to be $0.8 million to $3.4 million, or $0.01 to $0.03 per diluted share
- Adjusted EBITDA is projected to be $16.8 million to $18.3 million
- Revenue is expected to be $507.0 million to $514.0 million, reflecting growth of 47% to 49%
- Net income is projected to be $51.5 million to $54.1 million, or $0.51 to $0.54 per diluted share
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...